Cyperquat (MPP+), but not MPTP or Paraquat Inhibits Oxygen Consumption in Mitochondria from Rat Striatum

  • M. N. Hassan
  • J. H. Thakar
  • J. D. Grimes
Part of the Advances in Behavioral Biology book series (ABBI, volume 32)


l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) is known to induce parkinsonism in man and in several laboratory animal species1–4. MPTP binds to monoamine oxidase (MAO) sites in most brain areas, including the substantia nigra and striatum5. MAO oxidises MPTP to l-methyl-4-phenyl pyridinium ion (MPP+) which induces neurotoxicity by a mechanism(s) not yet elucidated. Pretreatment of animals with MAO-B inhibitors, for example, pargyline, prevents MPTP-induced parkinsonism6,7. In contrast, MAO-A inhibitors, such as clorgyline, is not effective in preventing MPTP-induced toxicity6,8.


Oxygen Consumption Rate Flavin Adenine Dinucleotide Flavin Adenine Dinucleotide Mitochondrial Preparation Phenyl Pyridinium 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    J.W. Langston, P. Ballard, J.W. Tetrud, and I. Irwin, “Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis”. Science 219:979 (1983).PubMedCrossRefGoogle Scholar
  2. 2.
    R.S. Burns, C.C. Chiueh, S.P. Markey, M.H. Ebert, D.M. Jacobowitz, and I.J. Kopin, “A Primate Model of Parkinsonism: Selective Destruction of Dopaminergic Neurons in the Pars Compacta of the Substantia Nigra by N-methyl-4-phenyl-l,2,3,6-tetrahydropyridine”. Proc. Natl. Acad. Sci. U.S.A., 80:4546 (1983).PubMedCrossRefGoogle Scholar
  3. 3.
    J.W. Langston, L.S. Forno, C.S. Rebert, and I. Irwin, “Selective Nigral Toxicity After Systemic Administration of l-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the Squirrel Monkey”. Brain Res., 292:390 (1984).PubMedCrossRefGoogle Scholar
  4. 4.
    R.E. Heikkila, A. Hess, and R.C. Duvoisin, “Dopaminergic Neurotoxicity of l-Methyl-4-Phenyl-1,2,5,6-tetrahydropyridine in Mice”. Science, 224:1451 (1984).PubMedCrossRefGoogle Scholar
  5. 5.
    J.A. Javitch, G.R. Uhl, and S.H. Snyder, “Parkinsonism-inducing Neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Characterization and Localization of Receptor Binding Sites in Rat and Human Brain”. Proc. Natl. Acad. Sci., U.S.A., 81:4591 (1984).PubMedCrossRefGoogle Scholar
  6. 6.
    R.E. Heikkila, L. Manzino, F.S. Cabbat, and R.C. Duvoisin, “Protection Against the Dopaminergic Neurotoxicity of l-methyl-4-phenyl-l,2,5,6-tetrahydropyridine by Monoamine Oxidase Inhibitors”. Nature, (London), 311:467 (1984).CrossRefGoogle Scholar
  7. 7.
    J.W. Langston, I. Irwin, E.B. Langston, and L.S. Forno, “Pargyline Prevents MPTP-induced Parkinsonism in Primates”. Science, 225:1480.(1984).PubMedCrossRefGoogle Scholar
  8. 8.
    K. Chiba, A. Trevor, and N. Castagnoli, Jr., “Metabolism of the Neurotoxic Tertiary Amine, MPTP, by Brain Monoamine Oxidase”. Biochem. and Biophys. Res. Commun., 120:574 (1984).CrossRefGoogle Scholar
  9. 9.
    J.H. Thakar, M.N. Hassan, and J.D. Grimes, “In vitro Effects of Dopamine Active Compounds on Mitochondrial Respiration and Oxidative Phosphorylation From Rat Cortex, Striatum and Liver. 15th Annual Meeting, Society for Neuroscience, Abstract #350.4 (1985).Google Scholar
  10. 10.
    D. Cavalla, M. Hadjiconstantinou, H.E. Laird II, and N.H. Neff, “Intracerebroventricular Administration of l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its Metabolite l-methyl-4-phenylpyridinium Ion (MPP+) Decrease Dopamine and Increase Acetylcholine in the Mouse Neostriatum”. Neuropharmacol., 24:585 (1985).CrossRefGoogle Scholar
  11. 11.
    A.J. Bradbury, B. Costall, A.M. Domeney, P. Jenner, M.E. Kelly, C.D. Marsden, and R.J. Naylor, “l-methyl-4-phenylpyridine is Neurotoxic to the Nigrostriatal Dopamine Pathway”. Nature 319:56 (1986).PubMedCrossRefGoogle Scholar
  12. 12.
    W.C. Koller, “Paraquat and Parkinson’s Disease”. Neurology, 36:1147 (1986).PubMedGoogle Scholar
  13. 13.
    A. Barbeau, L. Dallaire, N.T. Buu, J. Poirier, and E. Rucinska, “Comparative Behavioral, Biochemical and Pigmentary Effects of MPTP, MPP+ and Paraquat in Rana Pipiens”. Life Sci.37:1529 (1985).PubMedCrossRefGoogle Scholar
  14. 14.
    O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall, “Protein Measurement with Folin Phenol Reagent”. J. Biol. Chem., 193:265 (1951).PubMedGoogle Scholar
  15. 15.
    J.H. Thakar, M.N. Hassan, and J.D. Grimes, “In Vitro Effects of MPTP and Related Compounds Paraquat and Cyperquat (MPP+) on Oxidative Phosphorylation of Mitochondria from Rat Cortex, Striatum and Liver”. 16th Annual Meeting, Society for Neuroscience, Abstract #28.7 (1986).Google Scholar
  16. 16.
    I. Vyas, R.E. Heikkila, and W.J. Nicklas, “Studies on the Neurotoxicity of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine: Inhibition of NAD-linked Substrate Oxidation by its Metabolite, l-methyl-4-phenylpyri-dinium”. J. Neurochem., 46:1501 (1986).PubMedCrossRefGoogle Scholar
  17. 17.
    J. Poirier, and A. Barbeau, “l-methyl-4-phenyl-pyridinium-induced Inhibition of Nicotinamide Adenosine Dinucleotide Cytochrome c Reductase”. Neurosci. Lett. 62:7 (1985).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • M. N. Hassan
    • 1
  • J. H. Thakar
    • 1
  • J. D. Grimes
    • 1
  1. 1.Ottawa Civic HospitalOttawaCanada

Personalised recommendations